文献速递心律失常

房颤患者肾功能下降与口服抗凝药剂量调整的现状分析

Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation.
PubMed 文献 · Heart · 2020-01-07

本研究基于ORBIT-AF II注册研究,纳入6682例口服抗凝的房颤患者,随访2年发现23.1%出现肾功能恶化(CrCl下降>20%)。在4120例NOACs患者中,3.7%达到FDA推荐的减量标准,但仅20.1%实际减量;未减量者1年内大出血和出血住院风险更高。

要点

  • 房颤患者2年内约四分之一出现CrCl下降>20%,需定期监测肾功能。
  • NOACs治疗者中仅3.7%符合减量标准,但实际减量率仅20.1%。
  • 符合减量标准却未减量者,1年内大出血和出血住院风险增加。

核心结论

  • 美国实践中约四分之一房颤患者2年内CrCl下降>20%,但符合NOACs减量标准者仅20.1%实际减量,未减量者出血并发症更多。

研究设计与样本

  • 基于ORBIT-AF II注册研究,纳入6682例口服抗凝的房颤患者,来自220个中心,中位年龄72.0岁,57.1%男性,基线中位CrCl 80.1 mL/min。

主要发现

  • 1543例(23.1%)出现肾功能恶化(CrCl下降>20%),2年随访中NOACs组平均CrCl下降-6.63 mL/min,华法林组-6.16 mL/min。
  • 4120例NOACs患者中,154例(3.7%)CrCl下降达到FDA推荐的减量标准,其中仅31例(20.1%)实际减量。
  • 与适当减量者相比,未减量者1年内大出血发生率1.7% vs 0%,出血住院率2.6% vs 0%。

关键数值与推荐

  • 肾功能恶化定义为CrCl较基线下降>20%。
  • NOACs减量标准依据美国FDA批准的药品说明书。

临床怎么用

  • 对NOACs治疗的房颤患者应定期监测肾功能,及时根据CrCl下降情况按FDA标准调整剂量。
  • 符合减量标准而未减量者出血风险增加,应加强剂量调整的规范化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Non-vitamin K oral anticoagulants (NOACs) require dose adjustment for renal function. We sought to investigate change in renal function over time in patients with atrial fibrillation (AF) and whether those on NOACs have appropriate dose adjustments according to its decline. METHODS: We included patients with AF enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II registry treated with oral anticoagulation. Worsening renal function (WRF) was defined as a decrease of >20% in creatinine clearance (CrCl) from baseline. The US Food and Drug Administration (FDA)-approved package inserts were used to define the reduction criteria of NOACs dosing. RESULTS: Among 6682 patients with AF from 220 sites (median age (25th, 75th): 72.0 years (65.0, 79.0); 57.1% male; median CrCl at baseline: 80.1 mL/min (57.4, 108.5)), 1543 patients (23.1%) experienced WRF with mean decline in CrCl during 2 year follow-up of -6.63 mL/min for NOACs and -6.16 mL/min for warfarin. Among 4120 patients on NOACs, 154 (3.7%) patients had a CrCl decline sufficient to warrant FDA-recommended dose reductions. Of these, NOACs dosing was appropriately reduced in only 31 (20.1%) patients. Compared with patients with appropriately reduced NOACs, those without were more likely to experience bleeding complications (major bleeding: 1.7% vs 0%; bleeding hospitalisation: 2.6% vs 0%) at 1 year. CONCLUSIONS: In the US practice, about one-fourth of patients with AF had >20% decline in CrCl over time during 2 year follow-up. As a result, about 3.7% of those treated with NOACs met guideline criteria for dose reduction, but of these, only 20.1% actually had a reduction.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020. PMID: 31911503. doi:10.1136/heartjnl-2019-315792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。